文献速递心脑血管急症消化、代谢与肾脏急症

疑似心肌梗死患者0/1小时与0/3小时路径比较:随机对照试验的系统评价与个体参与者数据Meta分析

Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2026-10-29
一句话结论在疑似心肌梗死患者中,0/1小时路径与0/3小时路径的30天全因死亡或新发1型心肌梗死复合终点无统计学显著差异(OR 0.83,95%CI 0.45-1.53),且未缩短急诊停留时间或明确增加直接出院。

该系统评价与个体参与者数据Meta分析纳入5项随机对照试验、共110933例就诊(0/1小时路径55489例,0/3小时路径55444例),比较0/1小时与0/3小时肌钙蛋白检测路径的安全性和有效性。30天全因死亡或新发1型心肌梗死复合终点在0/1小时路径组为0.8%、0/3小时路径组为1.0%(随机效应合并OR 0.83,95%CI 0.45-1.53;I²=62.9%)。急诊停留时间0/1小时路径组为314分钟(IQR 211-481)、0/3小时路径组为308分钟(IQR 209-453)(合并几何均值比1.03,95%CI 0.85-1.25;I²=99.2%)。急诊直接出院率0/1小时路径组67.0%、0/3小时路径组65.8%(合并OR 1.31,95%CI 0.79-2.16;I²=97.8%)。作者认为两种路径短期不良事件率均低但合并安全性估计仍不精确,更早复查肌钙蛋白平均未缩短急诊停留时间或明确增加直接出院,研究间异质性大提示效果可能不统一适用于各医疗体系。

要点

  • 5项随机对照试验、110933例就诊的个体参与者数据Meta分析显示,0/1小时路径30天全因死亡或新发1型心肌梗死复合终点0.8%,0/3小时路径1.0%,合并OR 0.83(95%CI 0.45-1.53),未达统计学显著。
  • 急诊停留时间0/1小时路径组314分钟(IQR 211-481)vs 0/3小时路径组308分钟(IQR 209-453),合并几何均值比1.03(95%CI 0.85-1.25),异质性I²=99.2%。
  • 急诊直接出院率0/1小时路径组67.0% vs 0/3小时路径组65.8%,合并OR 1.31(95%CI 0.79-2.16),异质性I²=97.8%。
  • 研究间异质性大(安全性终点I²=62.9%、急诊停留时间I²=99.2%、直接出院I²=97.8%),作者认为治疗效果可能不会在各医疗体系间统一转化。
  • 作者认为,考虑从0/3小时路径转为0/1小时路径的医院,实施决策应纳入更广泛的诊断和组织层面考量。

适用人群与场景

  • 疑似心肌梗死患者,来自5项比较0/1小时与0/3小时路径的随机对照试验,共110933例就诊(0/1小时路径55489例,0/3小时路径55444例)。

处置流程与药物剂量

  • 0/1小时路径:在0小时和1小时采血检测肌钙蛋白进行早期风险分层。
  • 0/3小时路径:在0小时和3小时采血检测肌钙蛋白,即标准诊疗。

研究设计与关键结果

  • 研究类型:系统评价与个体参与者数据Meta分析,纳入5项随机对照试验,采用两阶段随机效应Meta分析;主要安全性终点在获得个体参与者数据后、数据统一前由原定的全因死亡或任何新发心肌梗死复合终点细化为30天全因死亡或新发1型心肌梗死复合终点。
  • 主要安全性终点:30天全因死亡或新发1型心肌梗死,0/1小时路径组446例(0.8%)vs 0/3小时路径组562例(1.0%),合并OR 0.83(95%CI 0.45-1.53;I²=62.9%;τ²=0.143)。
  • 主要有效性终点之一:急诊停留时间,0/1小时路径组314分钟(IQR 211-481)vs 0/3小时路径组308分钟(IQR 209-453),合并几何均值比1.03(95%CI 0.85-1.25;I²=99.2%;τ²=0.024)。
  • 主要有效性终点之二:急诊直接出院,0/1小时路径组37190例(67.0%)vs 0/3小时路径组36485例(65.8%),合并OR 1.31(95%CI 0.79-2.16;I²=97.8%;τ²=0.156)。
  • 5项试验中主要安全性终点定义不一致,且4项试验未报告全分析人群的急诊停留时间。

证据类型、等级与局限

  • 证据类型:系统评价与个体参与者数据Meta分析,纳入5项随机对照试验;PROSPERO注册号CRD420261383452。
  • 局限:5项试验中主要安全性终点定义不一致;4项试验未报告全分析人群的急诊停留时间;合并安全性估计仍不精确;研究间异质性大(安全性终点I²=62.9%、急诊停留时间I²=99.2%、直接出院I²=97.8%),提示治疗效果可能不会在各医疗体系间统一转化。

对床旁实践的改变

  • 作者认为,两种路径短期不良事件率均低,但合并安全性估计仍不精确,更早复查肌钙蛋白平均未缩短急诊停留时间或明确增加直接出院。
  • 作者认为,考虑从0/3小时路径转为0/1小时路径的医院,实施决策应纳入更广泛的诊断和组织层面考量。

指南或共识出处

  • Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials(Lancet)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In patients with suspected myocardial infarction, the 0/1 h pathway (blood draws at 0 h and 1 h) is recommended in current guidelines for early risk stratification. However, individual trials used different safety outcomes, and efficacy outcomes were inconclusive or not assessed. We conducted a systematic review and individual participant data meta-analysis of all randomised controlled trials to synthesise the totality of the evidence, assess heterogeneity across trials, and evaluate clinically relevant outcomes using harmonised definitions across trials.

METHODS: In this systematic review and individual participant data meta-analysis, we searched PubMed, Cochrane Central Register of Controlled Trials, Scopus, and the International Clinical Trials Registry Platform from inception to July 6, 2026, without language restrictions, for randomised trials comparing the safety and efficacy of 0/1 h versus 0/3 h pathways (blood draws at 0 h and 3 h, ie, standard care). Individual participant data were obtained and outcome definitions were harmonised. The primary analysis used a two-stage random-effects meta-analysis. After receipt of the individual participant data but before data harmonisation or analysis, the primary safety outcome was refined to a composite of all-cause death or new type 1 myocardial infarction within 30 days, from the originally specified composite of all-cause death or any new myocardial infarction. The primary efficacy outcomes were emergency department length of stay and direct discharge from the emergency department. This meta-analysis is registered with PROSPERO (CRD420261383452).

FINDINGS: Our systematic review identified five randomised trials, all of which provided individual participant data. Among these, the definition of the primary safety outcome varied, and in four trials emergency department length of stay was not reported for the whole analysis population. We included 110 933 patient presentations (55 489 managed with the 0/1 h pathway and 55 444 managed with the 0/3 h pathway). Within 30 days, all-cause death or new type 1 myocardial infarction occurred in 446 patient presentations (0·8%) with the 0/1 h pathway versus 562 patient presentations (1·0%) with the 0/3 h pathway (random-effects pooled odds ratio [OR] 0·83 [95% CI 0·45-1·53]; I2=62·9%; τ2=0·143). Emergency department length of stay was 314 min (IQR 211-481) in the 0/1 h pathway group versus 308 min (209-453) in the 0/3 h pathway group (random-effects pooled geometric mean ratio 1·03 [95% CI 0·85-1·25]; I2=99·2%; τ2=0·024). Direct discharge from the emergency department occurred in 37 190 patient presentations (67·0%) with the 0/1 h pathway versus 36 485 patient presentations (65·8%) with the 0/3 h pathway (random-effects pooled OR 1·31 [95% CI 0·79-2·16]; I2=97·8%; τ2=0·156).

INTERPRETATION: Across the available randomised trials, short-term adverse event rates were low with both pathways, but the pooled safety estimate remained imprecise. On average, earlier cardiac troponin retesting did not reduce emergency department length of stay or clearly increase direct discharge, and substantial between-study heterogeneity indicates that treatment effects might not translate uniformly across health-care systems. For hospitals considering transitioning from a 0/3 h to a 0/1 h pathway, implementation decisions should take broader diagnostic and organisational considerations into account.

FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, University Hospital Basel, University of Basel, and Foundation for Cardiovascular Research Basel.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Boeddinghaus J, Kunz M, Lopez-Ayala P, et al. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials. Lancet. 2026. PMID: 42956796. doi:10.1016/S0140-6736(26)01767-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。